報價延遲最少15分鐘:2024/05/16 04:08 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.18 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.74/0.19
|
|
企業價值
717.33M
|
| 資產負債 |
|
每股賬面淨值
-0.71
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
257.24M
|
|
每股收益
1.84
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/16 04:08 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States. |